SCHEMBL2000422

SCHEMBL2000422

COC(=O)Cc1ccc(Oc2ccc3c(cnn3COCC[Si](C)(C)C)c2N)c(OC)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.38
QPCT Q16769 1/20 0.37
QPCTL Q9NXS2 1/20 0.37
ALDH1A1 P00352 6/20 0.36
LMNA P02545 1/20 0.35
GAA P10253 2/20 0.35
MAPT P10636 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
GFER P55789 1/20 0.34
ABL1 P00519 1/20 0.34
RIN1 Q13671 1/20 0.34
ATM Q13315 1/20 0.34
PDGFRB P09619 1/20 0.34
KDR P35968 1/20 0.34
FLT3 P36888 1/20 0.34
KDM4E B2RXH2 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2000722 0.87 ALDH1A1 (0.37) SLC2A1ALDH1A1LMNAMAPTCYP1A2
SCHEMBL2006733 0.81 PTGDR (0.58) CYP3A4
SCHEMBL21810456 0.71 SUCNR1 (0.43) LMNAMAPTHPGDRXFP1
SCHEMBL14014556 0.71 ALPL (0.43) ALDH1A1LMNAGAAMAPTCYP1A2
SCHEMBL25298512 0.68 EGFR (0.37) ALDH1A1LMNAGAAATMKDR
SCHEMBL30565986 0.68 EGFR (0.37) ALDH1A1LMNAGAAATMKDR
SCHEMBL2002117 0.68 CYP3A4 (0.52) ALDH1A1LMNAGAAMAPTCYP1A2
SCHEMBL29460036 0.67 NPC1 (0.36) ALDH1A1LMNAGAAMAPTSMN1; SMN2
SCHEMBL24783374 0.67 NPC1 (0.36) ALDH1A1LMNAGAAMAPTSMN1; SMN2
SCHEMBL1534483 0.66 EGFR (0.34) KDRFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2164828-B1 COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION AMGEN INC (US) 2013-03-27 EP disclosed
US-7960567-B2 Compounds and methods useful for treating asthma and allergic inflammation AMGEN INC. (US) 2011-06-14 US disclosed
US-7960567-B2 Compounds and methods useful for treating asthma and allergic inflammation AMGEN INC. (US) 2011-06-14 US disclosed
EP-2164828-A2 COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION Amgen Inc. (US) 2010-03-24 EP disclosed
US-20080312270-A1 COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION AMGEN INC. 2008-12-18 US disclosed
US-20080312270-A1 COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION AMGEN INC. 2008-12-18 US disclosed
WO-2008137027-A2 COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION AMGEN INC. (US) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312270-A1 COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION CCL11, LTC4S, TSLP SLC2A1 4439/4885QPCT 367/4885QPCTL 1411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.